(Albany, New York)- 3rd Sep 2026, The market dynamics for Alopecia Areata are witnessing significant growth driven by increasing disease awareness, rising diagnosis rates, the growing recognition of its autoimmune nature, and the expansion of targeted therapies. Additionally, the approval and adoption of OLUMIANT (baricitinib), LITFULO (ritlecitinib), and LEQSELVI (deuruxolitinib), along with the development of promising pipeline candidates such as RINVOQ (upadacitinib), Coacillium (LH-8), Rezpegaldesleukin (NKTR-358), and STS01, are expected to further propel the Alopecia Areata market during the forecast period.
DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Alopecia Areata Market Insights, Epidemiology and Market Forecast – 2036.” This comprehensive report provides an in-depth understanding of Alopecia Areata, including historical and forecasted epidemiology, market trends, treatment scenarios, patient burden, and competitive landscape across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Key Takeaways from the Alopecia Areata Market
The market size for Alopecia Areata in the leading markets is expected to grow significantly by 2036.
The 7MM Alopecia Areata market was approximately USD 850 million in 2025, reflecting a 24.4% CAGR during 2022–2036.
According to DelveInsight’s estimates, Alopecia Areata reported approximately 800,000 prevalent cases and around 630,000 diagnosed prevalent cases in the United States in 2025.
In 2025, the United States accounted for the highest prevalent cases of Alopecia Areata, with approximately 800,000 cases, and the number is expected to increase by 2036.
In 2025, the United Kingdom reported the highest number of diagnosed prevalent cases of Alopecia Areata among EU4 and the UK, with approximately 330,000 cases, followed by Spain with around 180,000 cases, while Italy recorded nearly 100,000 cases.
In 2025, Japan reported approximately 170,000 diagnosed prevalent cases of Alopecia Areata in females and nearly 110,000 cases in males.
In 2025, females accounted for 63% of Alopecia Areata cases in EU4 and the UK, while males represented 37%.
In 2025, approximately 14% of Alopecia Areata cases in EU4 and the UK were mild, 45% moderate, and 41% severe.
The current treatment landscape for Alopecia Areata is limited, with three FDA-approved therapies, all belonging to the JAK inhibitor class.
OLUMIANT (baricitinib), developed by Eli Lilly and Company and Incyte Corporation, was the first JAK inhibitor approved for Alopecia Areata in 2022, marking a significant milestone in targeted treatment.
LITFULO (ritlecitinib), developed by Pfizer, was approved in 2023 as a selective JAK3 and TEC kinase inhibitor, expanding treatment options, including for adolescents.
LEQSELVI (deuruxolitinib), developed by Sun Pharmaceutical Industries, was launched in 2025 as a JAK1/2 inhibitor for adults with severe Alopecia Areata.
In 2025, the United States Alopecia Areata market size was around USD 500 million, accounting for approximately 53% of the total market.
The EU4 and UK market was estimated to be approximately USD 300 million in 2025, representing nearly 39% of the total 7MM market.
In 2025, the Japan Alopecia Areata market size was approximately USD 60 million.
Leading Alopecia Areata companies, including Eli Lilly and Company, Pfizer, Incyte Corporation, Sun Pharmaceuticals, AbbVie, Legacy Healthcare, Nektar Therapeutics, and others, are actively developing innovative therapies expected to transform the Alopecia Areata treatment landscape over the coming years.
Promising Alopecia Areata therapies in clinical development include RINVOQ (upadacitinib), Coacillium (LH-8), Rezpegaldesleukin (NKTR-358), STS01, Bempikibart (ADX-914), Ivarmacitinib (SHR-0302), Amlitelimab (SAR-445229), and IMG-007, among others.
Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/alopecia-areata-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr
Key Factors Driving the Alopecia Areata MarketRising Disease Awareness and Improved Diagnosis
Increasing awareness of Alopecia Areata as an autoimmune skin disease, combined with improvements in clinical evaluation and diagnostic techniques, is contributing to better disease recognition. Detailed examination, dermatoscopy or trichoscopy, hair pull tests, and additional investigations when required can support accurate diagnosis and disease assessment.
Expansion of Targeted JAK Inhibitor Therapies
The approval of JAK inhibitors has significantly transformed the Alopecia Areata treatment landscape. OLUMIANT, LITFULO, and LEQSELVI provide targeted approaches to immune pathways involved in hair loss. However, safety concerns associated with JAK inhibitors, including risks of infections, malignancies, cardiovascular events, thrombosis, and laboratory abnormalities, continue to create a need for additional treatment options.
Significant Unmet Need for Effective Long-term Treatments
Despite the availability of approved and off-label therapies, current treatments often provide unsatisfying responses and high relapse rates, particularly in more severe disease. Existing treatment options generally do not influence the long-term course of Alopecia Areata, highlighting the need for therapies capable of achieving more effective and sustained hair regrowth.
Robust Pipeline of Emerging Immunomodulatory Therapies
The Alopecia Areata pipeline is expanding beyond JAK inhibition, with emerging therapies targeting immune regulation, cytokine pathways, and tolerance restoration. Upadacitinib, Coacillium, Rezpegaldesleukin, STS01, Bempikibart, Ivarmacitinib, Amlitelimab, and IMG-007 represent a diverse range of approaches that may broaden future treatment options.
Alopecia Areata Competitive Landscape
The Alopecia Areata treatment landscape has evolved significantly with the introduction of targeted JAK inhibitors. Current management includes corticosteroids, immunosuppressants, immunomodulators, topical sensitizers or irritants, minoxidil, and other therapies. Topical corticosteroids are commonly used for localized disease, while systemic corticosteroids and other systemic therapies may be considered for more severe cases.
OLUMIANT (baricitinib), developed by Eli Lilly and Company and Incyte Corporation, became the first approved JAK inhibitor for Alopecia Areata in 2022. It targets specific immune pathways involved in hair loss and established a new targeted treatment approach for the disease.
LITFULO (ritlecitinib), developed by Pfizer, followed in 2023 as a selective JAK3 and TEC kinase inhibitor, while LEQSELVI (deuruxolitinib) from Sun Pharmaceutical Industries was launched in 2025 as a JAK1/2 inhibitor for adults with severe disease.
The emerging pipeline is increasingly focused on mechanisms beyond JAK inhibition. RINVOQ (upadacitinib) is an oral JAK1 selective inhibitor being evaluated in Phase III for severe Alopecia Areata, while Coacillium (LH-8) is a cutaneous immuno-inflammatory modulator being developed for moderate-to-severe disease. Rezpegaldesleukin (NKTR-358) targets IL-2 regulatory T-cell stimulation, while STS01 is being developed as a non-steroidal topical cytokine modulator.
These emerging therapies are expected to further reshape the Alopecia Areata treatment landscape over the forecast period.
Discover more about therapies set to grab major Alopecia Areata market share @ Alopecia Areata Treatment Landscape
Recent Developments in the Alopecia Areata Market
In January 2026, Legacy Healthcare reported plans to advance Coacillium (LH-8) into an international Phase III clinical trial for Alopecia Areata, following clearance from the US FDA.
In August 2025, AbbVie reported positive topline results from the second Phase III UP-AA trial evaluating upadacitinib (RINVOQ) for Alopecia Areata.
In July 2024, Sun Pharmaceutical Industries reported that the US FDA approved deuruxolitinib (LEQSELVI), a once-daily oral treatment, for severe Alopecia Areata.
In May 2024, Soterios Pharma reported promising Phase II trial results for STS-01 in mild-to-moderate Alopecia Areata. STS-01 was well tolerated with no significant adverse events reported, with full results anticipated to be presented later.
What is Alopecia Areata?
Alopecia Areata is a common autoimmune skin disease that causes hair loss on the scalp, face, and sometimes other areas of the body. It can affect people of all ages and both gender and may occur across different populations. Alopecia Areata is the second most common form of alopecia after androgenetic alopecia and often first appears during childhood.
The condition may present as small, coin-sized, round patches of baldness on the scalp, while hair loss may also affect the beard, eyebrows, eyelashes, body, and limbs. In some individuals, larger areas may be affected, potentially progressing to alopecia totalis, involving the entire scalp, or alopecia universalis, involving the entire body and scalp.
Evaluation involves a comprehensive medical and family history and detailed examination of the scalp, face, body, and nails. Dermatoscopy or trichoscopy and a hair pull test can support diagnosis and disease activity assessment. When diagnosis remains uncertain, additional investigations such as scalp biopsy, fungal culture, or serological testing may be performed.
Treatment aims to suppress immune activity and promote hair regrowth. Current approaches include topical and systemic corticosteroids, topical immunotherapy, topical anthralin, minoxidil, systemic immunosuppressive agents, immunomodulators, and JAK inhibitors. However, unpredictable disease progression, relapse, safety limitations, and variable treatment responses continue to create significant unmet needs.
Alopecia Areata Epidemiology Segmentation
The Alopecia Areata epidemiology section provides insights into the historical and current Alopecia Areata patient pool and forecasted trends across the seven major markets. The Alopecia Areata market report provides epidemiological analysis for the study period 2022–2036, segmented into:
Prevalent Cases of Alopecia Areata
Diagnosed Prevalent Cases of Alopecia Areata
Gender-specific Diagnosed Prevalent Cases of Alopecia Areata
Age Onset-based Diagnosed Prevalent Cases of Alopecia Areata
Severity-specific Diagnosed Prevalent Cases of Alopecia Areata
Patient Burden Assessment
Scope of the Alopecia Areata Market Report
Therapeutic Assessment: Current marketed and emerging therapies for Alopecia Areata
Alopecia Areata Market Dynamics: Key market forecast assumptions, pricing trends, analogue assessment, therapy uptake, market outlook, and market share dynamics
Key Companies: Eli Lilly and Company, Pfizer, Incyte Corporation, Sun Pharmaceuticals, AbbVie, Legacy Healthcare, Nektar Therapeutics, and others
Key Therapies: Baricitinib (OLUMIANT), Ritlecitinib (LITFULO), Deuruxolitinib (LEQSELVI), Upadacitinib (RINVOQ), Coacillium (LH-8), Rezpegaldesleukin (NKTR-358), STS01, Bempikibart (ADX-914), Ivarmacitinib (SHR-0302), Amlitelimab (SAR-445229), IMG-007, and others
Competitive Intelligence Analysis: SWOT Analysis and Attribute Analysis
Unmet Needs, KOL’s Views, Analyst’s Views, Alopecia Areata Market Access and Reimbursement
To know more about Alopecia Areata companies working in the treatment market, visit @ Alopecia Areata Clinical Trials and Therapeutic Assessment
Table of Contents
Alopecia Areata Market Report Introduction
Executive Summary for Alopecia Areata
Key Events of Alopecia Areata
Disease Background and Overview
Alopecia Areata Epidemiology and Patient Population
Country-Specific Patient Population of Alopecia Areata
Alopecia Areata Current Treatment and Medical Practices
Alopecia Areata Unmet Needs
Alopecia Areata Marketed Therapies
Alopecia Areata Emerging Therapies
Alopecia Areata Market Analysis
Key Opinion Leaders’ Views
Alopecia Areata Market Access and Reimbursement
Alopecia Areata Market Drivers
Alopecia Areata Market Barriers
Alopecia Areata Appendix
Alopecia Areata Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in the life sciences and healthcare industries. Founded in 2014, the company provides comprehensive market intelligence, epidemiology, and insights across pharmaceuticals, biotechnology, medical devices, and emerging therapies. DelveInsight helps healthcare organizations make informed strategic decisions through data-driven research and industry expertise.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kirti SharmaEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
